Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Bio-Path Holdings 1.711M share Secondary priced at $7.60 » 07:17
02/16/21
02/16
07:17
02/16/21
07:17
BPTH

Bio-Path Holdings

$8.88 /

-0.46 (-4.93%)

Roth Capital acted as…

Roth Capital acted as sole book running manager for the offering.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$8.88 /

-0.46 (-4.93%)

BPTH Bio-Path Holdings
$8.88 /

-0.46 (-4.93%)

11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$8.88 /

-0.46 (-4.93%)

Hot Stocks
Bio-Path Holdings receives third U.S. patent grant for DNAbilize tech » 07:15
02/10/21
02/10
07:15
02/10/21
07:15
BPTH

Bio-Path Holdings

$5.16 /

+0.02 (+0.39%)

Bio-Path Holdings…

Bio-Path Holdings announced that the United States Patent and Trademark Office has granted U.S. Patent No. 10,898,506 titled, "P-ethoxy nucleic acids for liposomal formulation." The new patent builds on earlier patents granted that protect the platform technology for DNAbilize, the Company's novel RNAi nanoparticle drugs. In addition, the United States Patent and Trademark Office has mailed an Issue Notification for a patent related to the Company's lead product candidate, prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib. Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2. The new patent is scheduled to issue as U.S. Patent No. 10,927,379 on February 23, 2021.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$5.16 /

+0.02 (+0.39%)

BPTH Bio-Path Holdings
$5.16 /

+0.02 (+0.39%)

11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$5.16 /

+0.02 (+0.39%)

BPTH Bio-Path Holdings
$5.16 /

+0.02 (+0.39%)

Over a quarter ago
Hot Stocks
Bio-Path Holdings doses first patient in Phase 1 trial of BP1002 » 07:08
11/19/20
11/19
07:08
11/19/20
07:08
BPTH

Bio-Path Holdings

$3.34 /

+0.05 (+1.52%)

Bio-Path Holdings…

Bio-Path Holdings announced the enrollment and dosing of the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed CLL or with relapsed, aggressive non-Hodgkin's lymphoma. Preclinical studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target, and the Company believes that its benign safety profile should enable BP1002 combination therapy with approved agents. A total of six evaluable patients will be treated with BP1002 monotherapy in a standard 3+3 design, with a starting dose of 20 mg/m2. The treatment cycle consists of two doses per week over four weeks, resulting in eight doses administered over twenty-eight days. The primary objectives of the study include safety and tolerability of escalating doses of BP1002, recommended Phase 2 dose of BP1002, pharmacokinetics of BP1002 and BP1002 activity on Bcl-2 expression. Secondary endpoints include several efficacy measurements of tumor response.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$3.34 /

+0.05 (+1.52%)

BPTH Bio-Path Holdings
$3.34 /

+0.05 (+1.52%)

11/16/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$3.34 /

+0.05 (+1.52%)

BPTH Bio-Path Holdings
$3.34 /

+0.05 (+1.52%)

Recommendations
Bio-Path Holdings price target lowered to $10 from $12 at H.C. Wainwright » 06:18
11/16/20
11/16
06:18
11/16/20
06:18
BPTH

Bio-Path Holdings

$3.35 /

-0.23 (-6.42%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Bio-Path Holdings to $10 from $12 and reiterates a Buy rating on the shares following the company's Q3 results.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$3.35 /

-0.23 (-6.42%)

BPTH Bio-Path Holdings
$3.35 /

-0.23 (-6.42%)

08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$3.35 /

-0.23 (-6.42%)

BPTH Bio-Path Holdings
$3.35 /

-0.23 (-6.42%)

Earnings
Bio-Path Holdings reports Q3 EPS (80c), one est. (87c) » 07:27
11/13/20
11/13
07:27
11/13/20
07:27
BPTH

Bio-Path Holdings

$3.58 /

+0.2 (+5.92%)

"We made meaningful…

"We made meaningful progress across our programs throughout the third quarter despite continued headwinds related to the COVID-19 pandemic. Importantly, enrollment continues in Stage 2 of our Phase 2 trial of prexigebersen (BP1001), a liposomal Grb2 antisense, as a combination treatment for patients suffering with acute myeloid leukemia (AML)," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "We further strengthened our intellectual property portfolio with a strategic patent providing broad protection for application of prexigebersen in the treatment of a variety of cancers in combination with front-line therapies. We remain on track to initiate a Phase 1 study of prexigebersen for the treatment of solid tumors by year end. This is a particularly important advancement for Bio-Path as it marks our first-in-human study in solid tumors, an area of significant need where current treatment options are often ineffective."

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$3.58 /

+0.2 (+5.92%)

BPTH Bio-Path Holdings
$3.58 /

+0.2 (+5.92%)

08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$3.58 /

+0.2 (+5.92%)

BPTH Bio-Path Holdings
$3.58 /

+0.2 (+5.92%)

Hot Stocks
Bio-Path Holdings receives notice of allowance for patent for prexigebersen » 07:24
10/22/20
10/22
07:24
10/22/20
07:24
BPTH

Bio-Path Holdings

$4.09 /

-0.01 (-0.24%)

Bio-Path Holdings…

Bio-Path Holdings announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company's lead product candidate, prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib. Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2. The new patent, titled, "Combination Therapy with Liposomal Antisense Oligonucleotides," will provide broad protection for application of prexigebersen in the treatment of a variety of cancers in combination with front-line therapies.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$4.09 /

-0.01 (-0.24%)

BPTH Bio-Path Holdings
$4.09 /

-0.01 (-0.24%)

08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$4.09 /

-0.01 (-0.24%)

BPTH Bio-Path Holdings
$4.09 /

-0.01 (-0.24%)

Hot Stocks
Bio-Path granted patent for p-ethoxy nucleic acids for liposomal formulation » 15:13
09/18/20
09/18
15:13
09/18/20
15:13
BPTH

Bio-Path Holdings

$4.23 /

+0.035 (+0.84%)

Bio-Path Holdings…

Bio-Path Holdings received a Notice of Allowance for its U.S. patent application 16/426,798, according to a post to the USPTO's website. Reference Link

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$4.23 /

+0.035 (+0.84%)

BPTH Bio-Path Holdings
$4.23 /

+0.035 (+0.84%)

08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18
08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$4.23 /

+0.035 (+0.84%)

BPTH Bio-Path Holdings
$4.23 /

+0.035 (+0.84%)

Recommendations
Bio-Path Holdings price target lowered to $12 from $18 » 11:23
08/17/20
08/17
11:23
08/17/20
11:23
BPTH

Bio-Path Holdings

$4.78 /

-0.21 (-4.21%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Bio-Path Holdings to $12 from $18 and keeps a Buy rating on the shares following the company's Q2 financial results. While Bio-Path has enrolled and dosed the first patient in the amended Stage 2 of the Phase 2 trial of prexigebersen in combination with frontline therapy decitabine and venetoclax for the treatment of acute myeloid leukemia, Chen says the FDA has requested that the treatment of high-risk myelodysplastic syndrome patients with the triple combination be conducted in a separate clinical trial, which may not start in the near-term.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

08/17/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright
05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

Recommendations
Bio-Path Holdings price target lowered to $12 from $18 at H.C. Wainwright » 11:22
08/17/20
08/17
11:22
08/17/20
11:22
BPTH

Bio-Path Holdings

$4.78 /

-0.21 (-4.21%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Bio-Path Holdings to $12 from $18 and reiterates a Buy rating on the shares following the company's Q2 results. The FDA requested that the treatment of high-risk myelodysplastic syndrome patients with the triple combination be conducted in a separate clinical trial, which may not start in the near term, Chen tells investors in a research note. As such, the analyst removed the MDS patient population from the model.

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

BPTH Bio-Path Holdings
$4.78 /

-0.21 (-4.21%)

On The Fly
Fly Intel: Pre-market Movers » 08:59
08/14/20
08/14
08:59
08/14/20
08:59
MESO

Mesoblast

$11.80 /

+ (+0.00%)

, NVAX

Novavax

$133.12 /

+8.69 (+6.98%)

, TSLA

Tesla

$1,620.60 /

+65.9 (+4.24%)

, SNGX

Soligenix

$2.06 /

-0.04 (-1.90%)

, BPTH

Bio-Path Holdings

$5.53 /

+0.79 (+16.67%)

, CFRX

ContraFect

$5.16 /

-0.24 (-4.44%)

, AMAT

Applied Materials

$65.02 /

-1.5 (-2.25%)

, DKNG

DraftKings

$36.08 /

+2.355 (+6.98%)

, BTAI

BioXcel Therapeutics

$44.71 /

+0.45 (+1.02%)

, BIDU

Baidu

$124.65 /

-1.425 (-1.13%)

, OCGN

Ocugen

$0.62 /

+0.0214 (+3.57%)

, IQ

iQIYI

$21.69 /

-0.52 (-2.34%)

, BEKE

KE Holdings

$37.41 /

+ (+0.00%)

Check out this morning's…

ShowHide Related Items >><<
TSLA Tesla
$1,620.60 /

+65.9 (+4.24%)

SNGX Soligenix
$2.06 /

-0.04 (-1.90%)

OCGN Ocugen
$0.62 /

+0.0214 (+3.57%)

NVAX Novavax
$133.12 /

+8.69 (+6.98%)

MESO Mesoblast
$11.80 /

+ (+0.00%)

IQ iQIYI
$21.69 /

-0.52 (-2.34%)

DKNG DraftKings
$36.08 /

+2.355 (+6.98%)

CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

BPTH Bio-Path Holdings
$5.53 /

+0.79 (+16.67%)

BIDU Baidu
$124.65 /

-1.425 (-1.13%)

AMAT Applied Materials
$65.02 /

-1.5 (-2.25%)

MESO Mesoblast
$11.80 /

+ (+0.00%)

08/14/20 Maxim
Mesoblast price target raised to $22 from $16 at Maxim
08/14/20 H.C. Wainwright
Mesoblast gets 'strong vote of confidence' from FDA panel, says H.C. Wainwright
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
05/28/20 Ladenburg
Mesoblast price target raised to $15.25 from $13 at Ladenburg
NVAX Novavax
$133.12 /

+8.69 (+6.98%)

08/12/20 B. Riley Securities
B. Riley FBR remain buyers of Novavax amid pullback
08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/06/20 H.C. Wainwright
Novavax price target raised to $290 from $132 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst downgrades
TSLA Tesla
$1,620.60 /

+65.9 (+4.24%)

08/14/20 BofA
Tesla upgraded to Neutral from Underperform at BofA
08/13/20 Morgan Stanley
Tesla upgraded to Equal Weight from Underweight at Morgan Stanley
08/13/20 Morgan Stanley
Tesla upgraded to Equal Weight from Underweight at Morgan Stanley
08/12/20 Wedbush
Tesla stock split 'a smart strategic move,' says Wedbush
SNGX Soligenix
$2.06 /

-0.04 (-1.90%)

07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
BPTH Bio-Path Holdings
$5.53 /

+0.79 (+16.67%)

05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

06/09/20
Fly Intel: Top five analyst initiations
06/09/20 Mizuho
ContraFect initiated with a Buy at Mizuho
06/08/20 Cantor Fitzgerald
ContraFect initiated with an Overweight at Cantor Fitzgerald
10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
AMAT Applied Materials
$65.02 /

-1.5 (-2.25%)

08/14/20 B. Riley Securities
Applied Materials price target raised to $82 from $72 at B. Riley FBR
08/14/20 Craig-Hallum
Applied Materials price target raised to $83 from $79 at Craig-Hallum
08/14/20 Deutsche Bank
Applied Materials price target raised to $75 from $70 at Deutsche Bank
08/14/20 Mizuho
Applied Materials price target raised to $77 from $70 at Mizuho
DKNG DraftKings
$36.08 /

+2.355 (+6.98%)

08/14/20 Jefferies
DraftKings positioned to lead after Q2 results, says Jefferies
08/12/20 Craig-Hallum
NJ sports betting up, iGaming revenue still strong, says Craig-Hallum
08/03/20 Deutsche Bank
William Hill upgraded to Buy from Hold at Deutsche Bank
07/31/20
Fly Intel: Top five analyst initiations
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

07/21/20 Canaccord
BioXcel Therapeutics price target raised to $120 from $71 at Canaccord
07/20/20 BMO Capital
BioXcel Therapeutics price target raised to $104 from $64 at BMO Capital
07/20/20 H.C. Wainwright
BioXcel Therapeutics price target raised to $200 from $120 at H.C. Wainwright
07/08/20 H.C. Wainwright
BioXcel Therapeutics price target raised to $120 from $95 at H.C. Wainwright
BIDU Baidu
$124.65 /

-1.425 (-1.13%)

07/28/20 Mizuho
Baidu price target lowered to $170 from $175 at Mizuho
07/02/20 Loop Capital
iQIYI price target raised to $23 from $20 at Loop Capital
06/15/20 Mizuho
Baidu valuation 'compelling' on overstated concerns, says Mizuho
05/20/20 KeyBanc
Baidu price target raised to $145 from $136 at KeyBanc
OCGN Ocugen
$0.62 /

+0.0214 (+3.57%)

06/01/20 H.C. Wainwright
H.C. Wainwright downgrades Ocugen to Neutral after OCU300 discontinuation
06/01/20 H.C. Wainwright
Ocugen downgraded to Neutral from Buy at H.C. Wainwright
03/30/20 H.C. Wainwright
H.C. Wainwright encouraged Ocugen's Phase 3 trial of OCU300 still on track
12/20/19 H.C. Wainwright
Ocugen initiated with a Buy at H.C. Wainwright
IQ iQIYI
$21.69 /

-0.52 (-2.34%)

08/14/20 New Street
iQIYI downgraded to Neutral from Buy at New Street
06/25/20 Oppenheimer
iQIYI downgraded to Perform at Oppenheimer on softer viewership data
06/25/20 Oppenheimer
iQIYI downgraded to Perform from Outperform at Oppenheimer
BEKE KE Holdings
$37.41 /

+ (+0.00%)

TSLA Tesla
$1,620.60 /

+65.9 (+4.24%)

SNGX Soligenix
$2.06 /

-0.04 (-1.90%)

OCGN Ocugen
$0.62 /

+0.0214 (+3.57%)

NVAX Novavax
$133.12 /

+8.69 (+6.98%)

IQ iQIYI
$21.69 /

-0.52 (-2.34%)

DKNG DraftKings
$36.08 /

+2.355 (+6.98%)

CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

BPTH Bio-Path Holdings
$5.53 /

+0.79 (+16.67%)

BIDU Baidu
$124.65 /

-1.425 (-1.13%)

AMAT Applied Materials
$65.02 /

-1.5 (-2.25%)

  • 13
    Aug
  • 29
    Jul
  • 19
    Jun
  • 22
    May
  • 20
    Feb
  • 14
    Feb
  • 10
    Dec
  • 26
    Sep
TSLA Tesla
$1,620.60 /

+65.9 (+4.24%)

NVAX Novavax
$133.12 /

+8.69 (+6.98%)

IQ iQIYI
$21.69 /

-0.52 (-2.34%)

DKNG DraftKings
$36.08 /

+2.355 (+6.98%)

BIDU Baidu
$124.65 /

-1.425 (-1.13%)

AMAT Applied Materials
$65.02 /

-1.5 (-2.25%)

TSLA Tesla
$1,620.60 /

+65.9 (+4.24%)

SNGX Soligenix
$2.06 /

-0.04 (-1.90%)

OCGN Ocugen
$0.62 /

+0.0214 (+3.57%)

NVAX Novavax
$133.12 /

+8.69 (+6.98%)

MESO Mesoblast
$11.80 /

+ (+0.00%)

IQ iQIYI
$21.69 /

-0.52 (-2.34%)

DKNG DraftKings
$36.08 /

+2.355 (+6.98%)

CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

BIDU Baidu
$124.65 /

-1.425 (-1.13%)

AMAT Applied Materials
$65.02 /

-1.5 (-2.25%)

TSLA Tesla
$1,620.60 /

+65.9 (+4.24%)

NVAX Novavax
$133.12 /

+8.69 (+6.98%)

MESO Mesoblast
$11.80 /

+ (+0.00%)

IQ iQIYI
$21.69 /

-0.52 (-2.34%)

DKNG DraftKings
$36.08 /

+2.355 (+6.98%)

CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

BIDU Baidu
$124.65 /

-1.425 (-1.13%)

AMAT Applied Materials
$65.02 /

-1.5 (-2.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.